Your Destination Now – Aug 29, 2023

Albert Bourla. Click to enlarge

Pfizer CEO Albert Bourla is now the highest-paid pharmaceutical executive globally, a report has found.

Citing information from In Vivo, independent journalist Jordan Schachtel of the Dossier shared this discovery in an Aug. 24 piece. The Greek-born drug bigwig recorded a salary of $33 million in 2022. Bourla has earned almost $100 million in compensation since 2019, he added.

Aside from compensation, Bourla has also earned tens of millions through the sale of Pfizer stock. Schachtel noted that at the end of 2022, the Pfizer CEO sold 222,328 shares of company stock to the tune of more than $6 million. Despite this, Bourla retains about 250,000 shares in the New York-based drug firm.

The independent journalist pointed out that Bourla collaborated with the governments of the U.S. and other countries “to loot billions of dollars from the treasuries of dozens of nations, striking deals in which Pfizer provided a ‘free vaccine’ that redirected all of their costs on to taxpayers instead of Pfizer.” Moreover, all of the profits earned from the Wuhan coronavirus (COVID-19) vaccines “went directly to Pfizer, allowing for the Pharma giant to publish record profits year after year.”

According to Schachtel, Pfizer’s profits from the COVID-19 pandemic mainly came from the sales of its mRNA vaccine and Paxlovid medication. “Without COVID-19, Pfizer would not have made any net income since 2019,” he added. Its vaccine bankrolled by billions of dollars in taxpayer funds was supposed to address SARS-CoV-2 infection, but failed in its intended purpose and even caused serious reactions in the form of blood clots.

“Pfizer succeeded in bamboozling the masses by committing statistical malpractice and outright scamming,” concluded Schachtel. “In further hyping the Pfizer shots, Bourla often engaged in fraudulent marketing practices, routinely falsely claiming the Pfizer mRNA shot was akin to a cure to the [Wuhan] coronavirus.”

BioNTech, Moderna execs also took home huge earnings

Bourla is not the only drug executive that raked in windfall earnings during the height of COVID-19. Schachtel also noted that Moderna CEO Stephane Bancel also became a billionaire “thanks to his large equity stake in the company.” According to In Vivo, Bancel receives almost $20 million in compensation annually.

Rhoda Wilson of the Daily Expose zoomed in on the Moderna CEO and other so-called “COVID billionaires” in an Aug. 16 piece. According to her, Bancel recorded a net worth of $4.3 billion in 2021. This increased to $4.6 billion the following year, before dropping slightly to $4.4 billion in 2023.

The Massachusetts-based vaccine maker was founded in 2010 and went public in December 2018. Wilson pointed out that Bancel, who became Moderna CEO in 2011, “owns roughly eight percent of the company.”

She also discussed Dr. Ugur Sahin, the CEO of BioNTech that partnered with Pfizer to develop the mRNA COVID-19 vaccine. He recorded a net worth of $4 billion in 2021, during the height of the pandemic. It increased to $5.3 billion in 2022, before slightly decreasing at an estimated $5 billion in 2023.

Sahin and his wife Dr. Ozlem Tureci, also the company’s chief medical officer, established BioNTech in 2008. The company went public 11 years later in 2019, with Sahin owning 17 percent as of writing.

“Sahin led BioNTech to start on a vaccine for the coronavirus in early 2020,” she wrote. “It partnered with Pfizer in March 2020 and got approval in December [of the same year].”

Wilson concluded: “Some became household names due to the ‘vaccines’ they helped develop. Others got rich by making everything from personal protective equipment and diagnostic tests to antibody treatments and software that helps authorities schedule vaccination campaigns.”

Source